Lorus Therapeutics (LRUSF.OB) Approved to Commence Phase I Clinical Trials for Cancer Drug LOR-253
Lorus Therapeutics announced this week that their Investigational New Drug (IND) application has been approved by the United States Food and Drug Administration (FDA) to begin Phase I human trials of their cancer drug LOR-253. The human trials will begin with a dose escalation trial in advanced or metastatic solid tumors with LOR-253 to assess safety, profile, tolerability and antitumor activity in cancer patients as well as pharmacokinetic and pharmacodynamics properties of LOR-253. The Phase I trials will be hosted at Memorial Sloan-Kettering Cancer Center in New York City. LOR-253, formerly LT-253, has selective and potent antitumor activity in a…